Patent number 369491 has been granted to IBC Pharmaceuticals Inc. that is titled T Cell redirecting bispecific antibodies for treatment of disease. During the patent prosecution, the patent examiner objected to this patent under section 3(d) of the Indian Patents Act. The patent applicant responded to this objection by stating that the T-cell redirecting complex in the claimed invention is new and not known in the prior art. Moreover, even the composition comprising the said complex is new and has not been published in any prior art. This patent falls under the category of chemical. Overall, this patent covers the method and compositions of T cell redirecting complexes, i.e, DNL complex, having a binding site for T-cell antigen and the other binding site for an antigen/pathogen.